The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis
Open accessAbstract
The optimal approach for empirical antibiotic therapy in patients with severe sepsis and septic shock remains controversial. A retrospective cohort study was conducted in the intensive care units of a university hospital. The data from 760 patients with severe sepsis or septic shock associated with Gram-negative bacteremia was analyzed. Among this cohort, 238 (31.3%) patients received inappropriate initial antimicrobial therapy (IIAT). The hospital mortality rate was statistically greater among patients receiving IIAT compared to those initially treated with an appropriate antibiotic regimen (51.7% versus 36.4%; P < 0.001). Patients treated with an empirical combination antibiotic regimen directed against Gram-negative bacteria (i.e., β-lactam plus aminoglycoside or fluoroquinolone) were less likely to receive IIAT compared to monotherapy (22.2% versus 36.0%; P < 0.001). The addition of an aminoglycoside to a carbapenem would have increased appropriate initial therapy from 89.7 to 94.2%. Similarly, the addition of an aminoglycoside would have increased the appropriate initial therapy for cefepime (83.4 to 89.9%) and piperacillin-tazobactam (79.6 to 91.4%). Logistic regression analysis identified IIAT (adjusted odds ratio [AOR], 2.30; 95% confidence interval [CI] = 1.89 to 2.80) and increasing Apache II scores (1-point increments) (AOR, 1.11; 95% CI = 1.09 to 1.13) as independent predictors for hospital mortality. In conclusion, combination empirical antimicrobial therapy directed against Gram-negative bacteria was associated with greater initial appropriate therapy compared to monotherapy in patients with severe sepsis and septic shock. Our experience suggests that aminoglycosides offer broader coverage than fluoroquinolones as combination agents for patients with this serious infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Self-citationIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Self-citationAntibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
Arias, C. A., & Murray, B. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0804651 · Cited by 1,027
Ventilator-associated Pneumonia Caused by Potentially Drug-resistant Bacteria
TROUILLET, J.-L., CHASTRE, J., VUAGNAT, A., JOLY-GUILLOU, M.-L., COMBAUX, D., DOMBRET, M.-C., & GIBERT, C. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9705064 · Cited by 885
Garnacho-Montero, J., Garcia-Garmendia, J. L., Barrero-Almodovar, A., Jimenez-Jimenez, F. J., Perez-Paredes, C., & Ortiz-Leyba, C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000098031.24329.10 · Cited by 718
Harbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
Micek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1306-1311.2005 · Cited by 526
Self-citationSingle or multiple daily doses of aminoglycosides: a meta-analysis
Barza, M., Ioannidis, J. P., Cappelleri, J. C., & Lau, J. (1996) · BMJ · doi:10.1136/bmj.312.7027.338 · Cited by 450
Paul, M., Lador, A., Grozinsky-Glasberg, S., & Leibovici, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003344.pub3 · Cited by 377
Before–after study of a standardized hospital order set for the management of septic shock*
Micek, S. T., Roubinian, N., Heuring, T., Bode, M., Williams, J., Harrison, C., Murphy, T., Prentice, D., Ruoff, B. E., & Kollef, M. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000241151.25426.d7 · Cited by 372
Self-citationDupont, H., Mentec, H., Sollet, J. P., & Bleichner, G. (2001) · Intensive Care Medicine · doi:10.1007/s001340000640 · Cited by 309
Leibovici, L., Paul, M., Poznanski, O., Drucker, M., Samra, Z., Konigsberger, H., & Pitlik, S. D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1127 · Cited by 280
Paul, M., Soares-Weiser, K., & Leibovici, L. (2003) · BMJ · doi:10.1136/bmj.326.7399.1111 · Cited by 267
Kollef, M. H. (2008) · Clinical Infectious Diseases · doi:10.1086/590061 · Cited by 248
Self-citationEffectiveness of Combination Antimicrobial Therapy for Pseudomonas aeruginosa Bacteremia
Chamot, E., Boffi El Amari, E., Rohner, P., & Van Delden, C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2756-2764.2003 · Cited by 218
Petrosillo, N., Ioannidou, E., & Falagas, M. E. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02061.x · Cited by 213
Heyland, D. K., Dodek, P., Muscedere, J., Day, A., & Cook, D. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0b013e31816203d6 · Cited by 202
Vidal, L., Gafter-Gvili, A., Borok, S., Fraser, A., Leibovici, L., & Paul, M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm193 · Cited by 158
Beardsley, J. R., Williamson, J., Johnson, J. W., Ohl, C. A., Karchmer, T. B., & Bowton, D. L. (2006) · CHEST Journal · doi:10.1378/chest.130.3.787 · Cited by 141
Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis*
Thiel, S. W., Asghar, M. F., Micek, S. T., Reichley, R. M., Doherty, J. A., & Kollef, M. H. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e318196206b · Cited by 111
Self-citationDhainaut, J.-F., Laterre, P., LaRosa, S. P., Levy, H. A., Garber, G. E., Heiselman, D., Kinasewitz, G. T., Light, R. B., Morris, P. E., Schein, R. M. H., et al. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000085089.88077.af · Cited by 95
Al‐Hasan, M. N., Wilson, J. W., Lahr, B. D., Thomsen, K. M., Eckel‐Passow, J. E., Vetter, E. A., Tleyjeh, I. M., & Baddour, L. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01231-08 · Cited by 85
Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for treating sepsis
Paul, M., Leibovici, L., Grozinsky‐Glasberg, S., Benuri‐Silbiger, I., & Soares‐Weiser, K. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003344 · Cited by 60
Micek, S. T., Isakow, W., Shannon, W. D., & Kollef, M. H. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.1.26.55615 · Cited by 45
Self-citationKollef, M. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000202128.30405.60 · Cited by 36
Self-citation
Cited by
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“at least one active agent being administered (110).”
BackgroundSevere Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Metadata
- Authors
- Micek, S. T., Welch, E. C., Khan, J., Pervez, M., Doherty, J. A., Reichley, R. M., & Kollef, M. H.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-05
- Volume
- 54
- Issue
- 5
- Pages
- 1742-1748
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2114449734
- Cited by
- 278
- References
- 33
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.